Polypharmacy in chronic liver disease patients: Implications for disease severity, drug-drug interaction, and quality of life

被引:2
|
作者
Farooq, Juveriya [1 ,2 ]
Sana, M. M.
Chetana, P. M. [1 ]
Almuqbil, Mansour [3 ]
Bhat, Nagapati Prabhakar [2 ]
Sultana, Rokeya [4 ]
Khaiser, UmaimaFarheen [5 ]
Asdaq, Syed Mohammed Basheeruddin [6 ]
Almalki, Mutlaq Eidhah M. [7 ]
Khormi, Amro Mohammed Sawadi [6 ,7 ]
Albraiki, Salem Ahmad [8 ]
Almadani, Moneer E. [9 ]
机构
[1] Shree Devi Coll Pharm, Dept Pharm Practice, Mangalore 574142, Karnataka, India
[2] Yenepoya Deemed Univ, Dept Pharmacol, Deralakatte 575018, Karnataka, India
[3] King Saud Univ, Coll Pharm, Dept Clin Pharm, Riyadh 11451, Saudi Arabia
[4] Yenepoya Deemed Univ, Yenepoya Pharm Coll & Res Ctr, Dept Pharmacognosy, Deralakatte 575018, Karnataka, India
[5] Yenepoya Deemed Univ, Yenepoya Pharm Coll & Res Ctr, Dept Pharm Practice, Deralakatte 575018, Karnataka, India
[6] AlMaarefa Univ, Coll Pharm, Dept Pharm Practice, Riyadh 13713, Saudi Arabia
[7] King Saud Univ Med City, Riyadh, Saudi Arabia
[8] King Abdul Aziz Med City, Dept Pharm, Riyadh, Saudi Arabia
[9] AlMaarefa Univ, Coll Med, Dept Clin Med, Riyadh 13713, Saudi Arabia
关键词
Polypharmacy; Drug-drug interaction; Chronic liver disease; Cirrhosis; Quality of life; BETA-BLOCKERS; CIRRHOSIS; QUESTIONNAIRE;
D O I
10.1016/j.jsps.2023.06.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Multiple prescriptions for different medications may be needed for chronic conditions, increasing the risk of polypharmacy. The WHO defined polypharmacy as ''the administration of many drugs at the same time or the administration of an excessive number of drugs". The primary goal of this study was to evaluate polypharmacy in patients with chronic liver disease and to identify potential drug-drug interactions associated with it. A cross-sectional study was conducted at a tertiary care hospital in Mangalore, Karnataka, for six months, from November 2020 to April 2021. The study involved 118 patients with chronic liver disease from various age groups. Data was gathered by analyzing patients' medical records kept on the ward and interviewing them individually. In admission and discharge prescriptions, polypharmacy was examined. Online interaction checkers from Drugs.com and Medscape were used to interpret potential drug-drug interactions. The SF-36 and Chronic Liver Disease Questionnaire were used to measure the quality of life. The data obtained were analyzed statistically to determine the significant correlation. The number of prescribed drugs was significantly correlated (P = 0.018) with the severity of liver disease in Child-Pugh categories B and C. Additionally, moderate polypharmacy reduced quality of life (P < 0.05), and the physical health category was significantly associated with disease severity (P < 0.05). Drug-drug interactions were found in 108 out of the 118 examined prescriptions, totaling 586 interactions in the admission list and 405 interactions in the discharge list. If the potentially serious main drug interaction identified in this study is not well monitored, it could lead to a serious, potentially fatal health condition. Despite being advised, safety is not always guaranteed by liver enzyme monitoring. Therefore, healthcare providers must take additional precautions to avoid inappropriate prescribing, minimize side effects, and ensure drug safety.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] The prevalence and severity of potential drug-drug interactions among adult polypharmacy patients at outpatient clinics in Jordan
    Nusair, Mohammad B.
    Al-Azzam, Sayer, I
    Arabyat, Rasha M.
    Amawi, Haneen A.
    Alzoubi, Karem H.
    Rabah, Asma A.
    SAUDI PHARMACEUTICAL JOURNAL, 2020, 28 (02) : 155 - 160
  • [22] DRUG-DRUG INTERACTION IN HUMAN LIVER CELLS
    Agishi, T.
    Akamatsu, M. M. A.
    Sato, T. T. S.
    Kawashima, N. N. K.
    Omi, K. K. O.
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2008, 31 (07): : 653 - 654
  • [23] Economic implications of potential drug-drug interactions in chronic pain patients
    Taylor, Robert, Jr.
    Pergolizzi, Joseph V., Jr.
    Puenpatom, R. Amy
    Summers, Kent H.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2013, 13 (06) : 725 - 734
  • [24] Potential drug-drug interactions in hospitalized patients with chronic heart failure and chronic obstructive pulmonary disease
    Roblek, Tina
    Trobec, Katja
    Mrhar, Ales
    Lainscak, Mitja
    ARCHIVES OF MEDICAL SCIENCE, 2014, 10 (05) : 920 - 932
  • [25] A tandem white shark algorithm approach for optimizing drug-disease and drug-drug interactions in multimorbidity and polypharmacy
    Al Khatib, Sultan M.
    BIOMEDICAL SIGNAL PROCESSING AND CONTROL, 2024, 87
  • [26] Drug dosage recommendations in patients with chronic liver disease
    Perianez Parraga, Leonor
    Martinez-Lopez, Iciar
    Ventayol Bosch, Pere
    Puigventos Latorre, Francesc
    Delgado Sanchez, Olga
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2012, 104 (04) : 165 - 184
  • [27] Clinical implications from drug-drug and drug-disease interactions in older people
    Gnjidic, Danijela
    Johnell, Kristina
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2013, 40 (05) : 320 - 325
  • [28] Disease-drug and drug-drug interaction in COVID-19: Risk and assessment
    Kumar, Devendra
    Trivedi, Neerja
    BIOMEDICINE & PHARMACOTHERAPY, 2021, 139
  • [29] Analysis of polypharmacy events and drug-drug interaction in COVID-19 therapy
    Pradiningsih, Anna
    Qiyaam, Nurul
    Nopitasari, Baiq Leny
    PHARMACY EDUCATION, 2023, 23 (02): : 133 - 138
  • [30] Potential Drug-Drug Interactions in Patients with coronary Artery Disease
    S. R. Secoli
    N. Danzi
    G. Lorenzi-Filho
    L. César
    F. Nunes
    A. Amaro
    L. Drager
    A. M. M. Reis
    Drug Safety, 2008, 31 : 885 - 885